Haley Thompson1, Kiran Thakur2. 1. New York Medical College, 40 Sunshine Cottage Road, Valhalla, New York, 10595, USA. 2. Division of Critical Care and Hospitalist Neurology, Department of Neurology, Columbia University Medical Center, 177 Fort Washington Avenue, Milstein Hospital, 8GS-300, New York, NY, 10032, USA. ktt2115@cumc.columbia.edu.
Abstract
PURPOSE OF REVIEW: This review highlights current knowledge in travel-related neuroinfectious diseases, providing insight on approaches to prevention, diagnosis, and treatment of infections of the central nervous system (CNS) in travelers and immigrants. RECENT FINDINGS: Updates on travel vaccine recommendations including vaccine-specific interactions with immunosuppressive agents, advances in Zika virus and dengue virus vaccine development, new diagnostic criteria for neurocysticercosis, updates on treatment approaches for tuberculosis meningitis. Increasing rates of travel are leading to the spread of known infectious diseases and the emergence of new diseases in travel medicine. Among these infections, neuroinfectious diseases carry significant morbidity and mortality. To reduce the effect of travel-related illness, appropriate pre-travel measures and up-to-date diagnostic and treatment strategies are essential for optimal outcomes. This review highlights important travel information relevant to neuroinfectious diseases for several populations including immunocompetent, immunocompromised, pregnant, and infant/children travelers. It also outlines the travel risk, clinical presentation, diagnosis, and management of a select list of neuroinfectious diseases by region, including neurocysticercosis, Zika virus, tuberculosis meningitis, rabies, and tick-borne encephalitis.
PURPOSE OF REVIEW: This review highlights current knowledge in travel-related neuroinfectious diseases, providing insight on approaches to prevention, diagnosis, and treatment of infections of the central nervous system (CNS) in travelers and immigrants. RECENT FINDINGS: Updates on travel vaccine recommendations including vaccine-specific interactions with immunosuppressive agents, advances in Zika virus and dengue virus vaccine development, new diagnostic criteria for neurocysticercosis, updates on treatment approaches for tuberculosis meningitis. Increasing rates of travel are leading to the spread of known infectious diseases and the emergence of new diseases in travel medicine. Among these infections, neuroinfectious diseases carry significant morbidity and mortality. To reduce the effect of travel-related illness, appropriate pre-travel measures and up-to-date diagnostic and treatment strategies are essential for optimal outcomes. This review highlights important travel information relevant to neuroinfectious diseases for several populations including immunocompetent, immunocompromised, pregnant, and infant/children travelers. It also outlines the travel risk, clinical presentation, diagnosis, and management of a select list of neuroinfectious diseases by region, including neurocysticercosis, Zika virus, tuberculosis meningitis, rabies, and tick-borne encephalitis.
Entities:
Keywords:
Encephalitis; Infections in travelers and immigrants; Meningitis; Parasitic infections; Vaccinations
Authors: O H Del Brutto; T E Nash; A C White; V Rajshekhar; P P Wilkins; G Singh; C M Vasquez; P Salgado; R H Gilman; H H Garcia Journal: J Neurol Sci Date: 2016-11-21 Impact factor: 3.181
Authors: T E Nash; G Singh; A C White; V Rajshekhar; J A Loeb; J V Proaño; O M Takayanagui; A E Gonzalez; J A Butman; C DeGiorgio; O H Del Brutto; A Delgado-Escueta; C A W Evans; R H Gilman; S M Martinez; M T Medina; E J Pretell; J Teale; H H Garcia Journal: Neurology Date: 2006-10-10 Impact factor: 9.910
Authors: R Bryan Rock; Michael Olin; Cristina A Baker; Thomas W Molitor; Phillip K Peterson Journal: Clin Microbiol Rev Date: 2008-04 Impact factor: 26.132
Authors: Macpherson Mallewa; Anthony R Fooks; Daniel Banda; Patrick Chikungwa; Limangeni Mankhambo; Elizabeth Molyneux; Malcolm E Molyneux; Tom Solomon Journal: Emerg Infect Dis Date: 2007-01 Impact factor: 6.883